allow more optimal dosing of cytotoxic chemotherapy. Trials to explore the latter question are still investigational. This commentary ad dresses the influence of HGFs, given as primary pro phylaxis, on the reduction of incidence of infections in patients with the basis of both phase II and III studies that have appeared in the literature. The number of days with fever, number of febrile neutropenic clays, use of an tibiotics, the number of documented infections, and the duration of hospitalization were analyzed as pa rameters of putative efficacy. In several phase II stud ies the incidence of infections in patients treated with with but the value of such observations is limited because the supportive care, including the use of antibi otic agents, has changed considerably over time.
ADMINISTRATION OF HGF AFTER STANDARD-DOSE CHEMOTHERAPY
ase III studies1 1 1 '1'1 concerning 1 the discrepancy between effects on duration of grannia and effects on documented infections is unknown but could be related to insufficient sta tistical power of the studies or to the individual characteristics of the patients and their underlying disease. Indeed, it should be emphasized that most chemotherapy schedules for nonleukemic disorders have been developed in an attempt to minimize the incidence and severity of neutropenia and are there fore rarely complicated by clinically or microbiologically documented infections.
ADMINISTRATION OF HGF AFTER HIGH-DOSE CHEMOTHERAPY
The potential of HGF to reduce the incidence of infections can be assessed more adequately in the context of conditioning regimens for an autologous bone marrow transplantation (ABMT), inasmuch as ABMT usually results in relatively long periods of profound granulocytopenia. Moreover, a more reli able assessment of the incidence of infections can be made because the patients are hospitalized and are available for adequate daily monitoring, ingly, the results of studies concerning HGF admin istration in patients treated with high-dose therapy are almost as conflicting as those obtained in patients with less severe granulocytopenia. It can be postulated that a significant decrease of the incidence of docuconvincing evidence for reduction of the incidence of infections attributable to accelerated neutrophil recovery. In light of this, only three phase III placebo-controlled studies in patients undergoing an ABMT,7'iy showed a dence of documented infections in patients treated with HGF. Nemunaitis et al.17 reported that 65 pa tients with lymphoid malignancies who were receiving rhGM-CSF (250 mg/m2/day) after ABMT had statis tically significant fewer infections than 63 placeboversus 30%). Similarly, Link et in possible relation to enhanced host de~ and other drugs. Some studies reported that the duration of antibiotic treatment and hos pital stay were significantly shorter in the group of patients treated with HGF. However, this is de batable as true evidence of infection because an tibiotics were given mostly for fever only. The reason the duration of use of antibiotics cannot be used as a parameter of infection is the correlation between duration of granulocytopenia and use of s: in most st il count (ANC) % to r rose above 500 per microliter. ies9,17,14,22 HGF administration cost saving in the range of 25% to 35% in patients undergoing an ABMT.21' This was achieved mainly by reducing the duration of hospitalization, a ma jor cost factor in the management of neutropenia. Considering the possibility of the occurrence of an overwhelming infection in patients with profound granulocytopenia, most physicians will keep these patients hospitalized. Therefore the duration of a hospital stay is directly correlated with the pres ence of neutropenia, but it is questionable whether H G F is truly saving cost, considering the fact that the incidence of documented infections was not reduced in the vast majority of studies. Improved diagnostic facilities to discriminate pa tients with an infection from those with a nonins cause of fever, as well as better e easy access to a hospital, may offer better : occur rence of mucositis is associated with both radiotherapy and chemotherapeutic regimens, particularly anthra>e cytarabine.
There are no convincing data from the phase III trials that decrease inci dence of gram-negative infections. On the other hand, one should take into account that the use of prophylactic antibacterial agents has diminished and curtailed the incidence of gram-negative in fections during neutropenia. Therefore the size of the trials done is probably too small to disclose a beneficial influence. In the trials of Nemunaitis et al.17 and Link et al.,IK the difference in infection rate was attributable to differences in infections caused by gram-positive bacteria. The number of fungal infections encountered was too low to al low any conclusion, but in patients with a high risk for fungal infections the use of hematopoietic growth factors is attractive from a theoretical point of view. The risk for fungal infections in creases with prolonged neutropenia,•1 C I and it is known that antifungal therapy is more effective after neutrophil recovery. Furthermore, in vitro studies show that G-CSF potentiates anti-eandida growth inhibitory activity of polymorphonuclear It must be concluded that, besides granu locytopenia, numerous factors determine the risk of infection in patients treated with chemotherapy and radiotherapy, for example, mucosal damage, central venous catheters, environment, state a ) kind of underlying disease, and supportive strate gies used. To allow a final assessment of the pu tative clinical benefit of HGFs, further data on hard end points such as documented infection are ultimately required. This warrants carefully de signed randomized clinical trials that have tt balanced with respect to the major risk factors, which may necessitate stratification, particularly if the number of patients to be entered is expected to be limited. It is mandatory that adequate trials on the options and limitations of the use of HGFs are performed.
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